Drugs / CD19-directed CAR-T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03463928 | Oct 2017 → Jun 2019 | lymphoid leukemia | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02537977 | Jul 2015 → Jun 2020 | leukemia, lymphoma | Shanghai Tongji Hospital, Tongji University School of Medicine | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04340154 | May 2020 → May 2024 | acute lymphoblastic leukemia | Beijing Boren Hospital | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-directed CAR-T cells | “Patients were initially infused with CD19-directed CAR T cells intravenously” PMID 37863088 ↗ Oct 2023 |
| Known as | anti-CD19 CAR-T cells | “The main purpose of the study is to assess the safety and efficacy of the treatment with anti-CD19 CAR-T cells in the patients with chemotherapy resistant or refractory CD19...” NCT02537977 ↗ |
| Action | Deplete | “CAR-T cell mediated targeted elimination of CD19 expressing B cells” NCT03463928 ↗ |
| Modality | Cell therapy | “Autologous 2nd generation CD19-directed CAR-T cells” NCT02537977 ↗ |
| Route | Intravenous | “CD19-directed CAR-T cell infusion will be given by vein” NCT02537977 ↗ |
| Target | CD19 | “genetically modifying these specific cells with lentivirus to attack CD19 positive cells” NCT02537977 ↗ |